TMPRSS2 and prostate carcinoma: Cancer outlier profile analysis (COPA) was developed to identify transcripts up-regulated in only a small subset of cancer samples[1], and has successfully been used to identify recurrent TMPRSS2 gene fusions in prostate cancer.